|
1
|
Espie M: The management of breast cancer.
Diagn Interv Imaging. 95:753–757. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shimizu C: Breast cancer in young women:
Its biological and clinical uniqueness and needs of comprehensive
care. Breast Cancer. 21:641–642. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li T, Mello-Thoms C and Brennan PC:
Descriptive epidemiology of breast cancer in China: Incidence,
mortality, survival and prevalence. Breast Cancer Res Treat.
159:395–406. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sorscher S: Prognosis of patients with
multifocal breast cancer. Hum Pathol. 84:335–336. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Plichta JK: Breast cancer prognostic
staging and internal mammary lymph node metastases: A brief
overview. Chin Clin Oncol. 8:S112019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Van Langenberg A: Prognosis after breast
recurrence following conservative surgery and radiotherapy in
patients with node-negative breast cancer. Br J Surg. 87:681–683.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hwang J, Min BH, Jang J, Kang SY, Bae H,
Jang SS, Kim JI and Kim KM: MicroRNA expression profiles in gastric
carcinogenesis. Sci Rep. 8:143932018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lee YS and Dutta A: MicroRNAs in cancer.
Annu Rev Pathol. 4:199–227. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. Nature.
435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mohr AM and Mott JL: Overview of microRNA
biology. Semin Liver Dis. 35:3–11. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yates LA, Norbury CJ and Gilbert RJ: The
long and short of microRNA. Cell. 153:516–519. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Iorio MV and Croce CM: MicroRNA
dysregulation in cancer: Diagnostics, monitoring and therapeutics.
A comprehensive review. EMBO Mol Med. 4:143–159. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kallioniemi A: Molecular signatures of
breast cancer-predicting the future. N Engl J Med. 347:2067–2068.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xu B, Liu J, Xiang X, Liu S, Zhong P, Xie
F, Mou T and Lai L: Expression of miRNA-143 in pancreatic cancer
and its clinical significance. Cancer Biother Radiopharm.
33:373–379. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zheng L, Jiao W, Song H, Qu H, Li D, Mei
H, Chen Y, Yang F, Li H, Huang K and Tong Q: miRNA-558 promotes
gastric cancer progression through attenuating Smad4-mediated
repression of heparanase expression. Cell Death Dis. 7:e23822016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xiao S, Zhu H, Luo J, Wu Z and Xie M:
miR425-5p is associated with poor prognosis in patients with breast
cancer and promotes cancer cell progression by targeting PTEN.
Oncol Rep. 42:2550–2560. 2019.PubMed/NCBI
|
|
18
|
Li S, Xu JJ and Zhang QY: MicroRNA-132-3p
inhibits tumor malignant progression by regulating
lysosomal-associated protein transmembrane 4 beta in breast cancer.
Cancer Sci. 110:3098–3109. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tang W, Zhang X, Tan W, Gao J, Pan L, Ye
X, Chen L and Zheng W: miR-145-5p suppresses breast cancer
progression by inhibiting SOX2. J Surg Res. 236:278–287. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jiang L, Yang W, Bian W, Yang H, Wu X, Li
Y, Feng W and Liu X: MicroRNA-623 targets cyclin D1 to inhibit cell
proliferation and enhance the chemosensitivity of cells to
5-fluorouracil in gastric cancer. Oncol Res. 27:19–27. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wei S, Zhang ZY, Fu SL, Xie JG, Liu XS, Xu
YJ, Zhao JP and Xiong WN: Hsa-miR-623 suppresses tumor progression
in human lung adenocarcinoma. Cell Death Dis. 7:e23882016.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen Y, Peng S, Cen H, Lin Y, Huang C,
Chen Y, Shan H, Su Y and Zeng L: MicroRNA hsa-miR-623 directly
suppresses MMP1 and attenuates IL-8-induced metastasis in
pancreatic cancer. Int J Oncol. 55:142–156. 2019.PubMed/NCBI
|
|
23
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li G, Hu J and Hu G: Biomarker studies in
early detection and prognosis of breast cancer. Adv Exp Med Biol.
1026:27–39. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li Q, Wang Y, Hu R and Yang G:
Dysregulation of SPRR3/miR-876-3p axis contributes to tumorigenesis
in non-small-cell lung cancer. Onco Targets Ther. 13:2411–2419.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sahami-Fard MH, Kheirandish S and Sheikhha
MH: Expression levels of miR-143-3p and −424-5p in colorectal
cancer and their clinical significance. Cancer Biomark. 24:291–297.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang Z, Zhang J, Li J, Geng H, Zhou B,
Zhang B and Chen H: miR-320/ELF3 axis inhibits the progression of
breast cancer via the PI3K/AKT pathway. Oncol Lett. 19:3239–3248.
2020.PubMed/NCBI
|
|
30
|
Feng Y, Yang C, Hu D, Wang X and Liu X:
miR-675 promotes disease progression of non-small cell lung cancer
via activating NF-κB signaling pathway. Cell Mol Biol
(Noisy-le-grand). 63:7–10. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu W, Xu Y, Guan H and Meng H: Clinical
potential of miR-940 as a diagnostic and prognostic biomarker in
breast cancer patients. Cancer Biomark. 22:487–493. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Qiu C, Huang F, Zhang Q, Chen W and Zhang
H: miR-205-3p promotes proliferation and reduces apoptosis of
breast cancer MCF-7 cells and is associated with poor prognosis of
breast cancer patients. J Clin Lab Anal. 33:e229662019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hamam R, Ali AM, Alsaleh KA, Kassem M,
Alfayez M, Aldahmash A and Alajez NM: microRNA expression profiling
on individual breast cancer patients identifies novel panel of
circulating microRNA for early detection. Sci Rep. 6:259972016.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li Q, Liu J, Jia Y, Li T and Zhang M:
miR-623 suppresses cell proliferation, migration and invasion
through direct inhibition of XRCC5 in breast cancer. Aging (Albany
NY). 12:10246–10258. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bi CW, Zhang GY, Bai Y, Zhao B and Yang H:
Increased expression of miR-153 predicts poor prognosis for
patients with prostate cancer. Medicine (Baltimore). 98:e167052019.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zeng B, Li Y, Feng Y, Lu M, Yuan H, Yi Z,
Wu Y, Xiang T, Li H and Ren G: Downregulated miR-1247-5p associates
with poor prognosis and facilitates tumor cell growth via
DVL1/Wnt/β-catenin signaling in breast cancer. Biochem Biophys Res
Commun. 505:302–308. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Das J, Gayvert KM and Yu H: Predicting
cancer prognosis using functional genomics data sets. Cancer
Inform. 13 (Suppl 5):S85–S88. 2014.
|
